Tysabri
What Tysabri is used for
Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1) or Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Tysabri
- Active substance
- natalizumab
- Disease area
- Multiple Sclerosis
- Medicine group
- Monoclonal antibodies
- ATC code
- L04AG03
- Marketing authorisation holder
- Biogen Netherlands B.V.
- Authorised in the EU since
- 2006
Official information
In the USA
In India
- Natalizumab: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tysabri used for?
Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1) or Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increas…
What is the active substance in Tysabri?
Tysabri contains natalizumab.
Who makes Tysabri?
The EU marketing authorisation holder is Biogen Netherlands B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU